Zymeworks Closed Acquisition of Theravance Biopharma
The transaction uses non-recourse debt to secure a share of respiratory drug profit flows.
Updated on Sept. 28, 2026 in Corporate Finance
Live Poll
Do you believe major corporate mergers generally benefit the market and consumers?
Zymeworks has finalized its acquisition of Theravance Biopharma for $17.00 per share. The deal aims to diversify cash flows and bolster the firm's R&D strategy through the integration of key assets.
Why it matters
The acquisition shifts Zymeworks’ financial structure by adding $350 million in non-recourse debt, which will be serviced through assigned profit-share payments. This move provides the company with immediate access to established U.S. revenue streams to support long-term development projects.
Zymeworks funded the acquisition with $350 million in non-recourse notes and $217.5 million in cash, while project-based debt service is tied to 75% of YUPELRI profit flows. The company anticipates 2026 revenue of $278 million to $292 million and Adjusted EBITDA of $114 million to $128 million.
The players
Zymeworks
A biotechnology firm that develops multifunctional biotherapeutics and focuses on oncology drug discovery.
Theravance Biopharma
A biopharmaceutical company with a portfolio of respiratory therapies including the YUPELRI and TRELEGY ELLIPTA assets.
OMERS
A major pension fund manager providing the $350 million non-recourse note used to finance the transaction.
The details
Zymeworks structured this deal to preserve its core liquidity by tethering debt repayment directly to the performance of the YUPELRI asset. By assigning 75% of YUPELRI’s U.S. profit-share cash flows to its lender, OMERS, the firm minimizes the impact on its operational balance sheet. Following the deal, Theravance Biopharma common stock was delisted from the Nasdaq as Zymeworks integrated its R&D and intellectual property assets.
Timeline
The merger agreement was announced on June 29, 2026.
The transaction completion was announced on September 28, 2026.
A non-cash income tax benefit may be recognized in Q4 2026.
A $100 million TRELEGY ELLIPTA milestone payment is anticipated in Q1 2027.
Market Landscape
The transaction follows the pattern of consolidating specialized biopharma assets to bridge the gap between early-stage R&D and mature, durable revenue. It aligns with the 2026 corporate delisting requirements for Nasdaq-listed companies that undergo full acquisition and integration into parent entities.
Operators should monitor how non-recourse debt structures tied to specific product cash flows affect the acquirer’s long-term R&D flexibility. Management teams should evaluate whether these debt-financed acquisitions are sustainable based on the projected 2026 revenue targets.
The takeaway
This acquisition highlights the use of specialized debt financing to acquire assets without depleting operating cash reserves. Operators should track how the $100 million milestone payment in Q1 2027 impacts the company’s ability to meet its 2026 Adjusted EBITDA projection of $114 million to $128 million.
What happens next
Zymeworks is scheduled to potentially receive a $100 million milestone payment related to TRELEGY ELLIPTA in the first quarter of 2027.
Further reading
For more on industry consolidation trends, visit the Corporate Finance section.
Live Poll
Do you believe major corporate mergers generally benefit the market and consumers?
